New targets for schizophrenia treatment beyond the dopamine hypothesis

Albert C. Yang, Shih Jen Tsai*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

118 Scopus citations

Abstract

Schizophrenia has been primarily associated with dopamine dysfunction, and treatments have been developed that target the dopamine pathway in the central nervous system. However, accumulating evidence has shown that the core pathophysiology of schizophrenia might involve dysfunction in dopaminergic, glutamatergic, serotonergic, and gamma-aminobutyric acid (GABA) signaling, which may lead to aberrant functioning of interneurons that manifest as cognitive, behavioral, and social dysfunction through altered functioning of a broad range of macro- and microcircuits. The interactions between neurotransmitters can be modeled as nodes and edges by using graph theory, and oxidative balance, immune, and glutamatergic systems may represent multiple nodes interlocking at a central hub; imbalance within any of these nodes might affect the entire system. Therefore, this review attempts to address novel treatment targets beyond the dopamine hypothesis, including glutamate, serotonin, acetylcholine, GABA, and inflammatory cytokines. Furthermore, we outline that these treatment targets can be possibly integrated with novel treatment strategies aimed at different symptoms or phases of the illness. We anticipate that reversing anomalous activity in these novel treatment targets or combinations between these strategies might be beneficial in the treatment of schizophrenia.

Original languageEnglish
Article number1689
JournalInternational Journal Of Molecular Sciences
Volume18
Issue number8
DOIs
StatePublished - 3 Aug 2017

Keywords

  • Dopamine hypothesis
  • Novel treatment target
  • Schizophrenia

Fingerprint

Dive into the research topics of 'New targets for schizophrenia treatment beyond the dopamine hypothesis'. Together they form a unique fingerprint.

Cite this